Mammalian Target of Rapamycin and Autosomal Dominant Polycystic Kidney Disease

Transplantation Proceedings

Volumn 41, Issue 6 SUPPL., 2009, Pages

  Wuthrich R P ^a   Serra, A L ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

ARTICLE; CLINICAL TRIAL; DISEASE COURSE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERVENTION STUDY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY;

GENES, DOMINANT; HUMANS; KIDNEY DISEASES, CYSTIC; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROTEIN KINASES;

EID: 67949086546     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.097     Document Type: Article

References (23)

1. Grantham J.J. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 359 (2008) 1477
2. Harris P.C., and Torres V.E. Polycystic kidney disease. Annu Rev Med 60 (2009) 321
3. Ibraghimov-Beskrovnaya O. Molecular pathogenesis of ADPKD and development of targeted therapeutic options. Nephrol Dial Transplant 22 (2007) 3367
4. Torres V.E., Harris P.C., and Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 369 (2007) 1287
5. Torres V.E. Vasopressin antagonists in polycystic kidney disease. Semin Nephrol 28 (2008) 306
6. Mostov K.E. mTOR is out of control in polycystic kidney disease. Proc Natl Acad Sci U S A 103 (2006) 5247
7. Shillingford J.M., Murcia N.S., Larson C.H., et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103 (2006) 5466
8. Tao Y., Kim J., Schrier R.W., et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16 (2005) 46
9. Wahl P.R., Serra A.L., Le Hir M., et al. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2 (2006) 598
10. Wu M., Wahl P.R., Le Hir M., et al. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 30 (2007) 253
11. Walz G. Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel?. Nephrol Dial Transplant 21 (2006) 1752
12. Bello-Reuss E., Holubec K., and Rajaraman S. Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int 60 (2001) 37
13. Wei W., Popov V., Walocha J.A., et al. Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study. Kidney Int 70 (2006) 1261
14. Bernhardt W.M., Wiesener M.S., Weidemann A., et al. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am J Pathol 170 (2007) 830
15. Berthier C.C., Wahl P.R., Le Hir M., et al. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 23 (2008) 880
16. Guba M., von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8 (2002) 128
17. Serra A.L., Kistler A.D., Poster D., et al. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrol 8 (2007) 13
18. Franz K.A., and Reubi F.C. Rate of functional deterioration in polycystic kidney disease. Kidney Int 23 (1983) 526
19. Grantham J.J., Torres V.E., Chapman A.B., et al., CRISP Investigators. Volume progression in polycystic kidney disease. N Engl J Med 354 (2006) 2122
20. Kistler A.D., Poster D., Krauer F., et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 75 (2009) 235
21. Grantham J.J., Chapman A.B., and Torres V.E. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 1 (2006) 148
22. Qian Q., Du H., King B.F., et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 19 (2008) 631
23. Kauffman H.M., Cherikh W.S., Cheng Y., et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 (2005) 883